Form 4: Inozyme Pharma CFO Increases Stake Through Employee Stock Purchase Plan

Sanjay Subramanian, SVP, CFO & Head of BD of Inozyme Pharma, Inc., acquired 6,813 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Sanjay Subramanian, the Senior Vice President, Chief Financial Officer, and Head of Business Development for Inozyme Pharma, Inc., acquired additional shares of the company's common stock.
• The transaction involved the acquisition of 6,813 shares of common stock.
• The shares were purchased at a price of $0.74 per share.
• The acquisition was made pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP).
• The purchase period for these shares was from April 1, 2025, through June 25, 2025.
• The purchase price of $0.74 per share represents 85% of the closing price of the Issuer's common stock on April 1, 2025, which was the first trading day of the purchase period.
• Following this transaction, Sanjay Subramanian beneficially owns a total of 39,701 shares of Inozyme Pharma, Inc. common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive through an employee stock purchase plan is generally viewed as a positive signal of confidence in the company's future prospects and aligns management's interests with those of shareholders.

Positives

• A key executive, the SVP, CFO & Head of BD, increased their direct ownership in the company, which can signal confidence in future performance.
• The acquisition was made through an Employee Stock Purchase Plan (ESPP), indicating participation in a standard employee benefit program designed to align employee and shareholder interests.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Sanjay Subramanian, SVP, CFO & Head of BD, acquired shares through the company's 2020 Employee Stock Purchase Plan.

Industry Context

Insider purchases, particularly by senior executives like a CFO, are generally viewed positively in the biotechnology and pharmaceutical industries as they can signal management's confidence in the company's prospects and valuation. Employee Stock Purchase Plans are common mechanisms for employee ownership and alignment.

Comparison to Industry Standards

• Employee Stock Purchase Plans (ESPPs) are a standard component of compensation and benefits packages across many industries, including biotechnology, designed to encourage employee ownership.
• The discount offered (15% off the lower of the start or end period price, effectively 85% of the start price in this case) is typical for ESPP programs, aligning with common industry practices for such plans.

Related Party Transactions

• The transaction involves the purchase of shares by a company executive (Sanjay Subramanian) from the company (Inozyme Pharma, Inc.) through a pre-established Employee Stock Purchase Plan (ESPP), which is a common form of related-party transaction for employee benefits.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive indicator of management's belief in the company's value and future, potentially boosting investor confidence.
• Employees: The transaction highlights the availability and utilization of the company's ESPP, which can be a positive for employee morale and retention by offering a mechanism for ownership.

Key Dates

Recommendation

Keywords

Inozyme Pharma, INZY, Sanjay Subramanian, CFO, Employee Stock Purchase Plan, ESPP, Insider Transaction, Common Stock, Beneficial Ownership